DES was a form of synthetic estrogen marketed to women in the mid-20th century, and an estimated five to 10 million women took it while pregnant. The drug was later found to cause miscarriage and a rare form of vaginal cancer in girls exposed in the womb. Advocates today say the legacy of DES reveals an unspoken gender bias in the medical industry—one that still persists today. Full article and interview with Suzanne Robotti, Founder/President, MedShadow, here.
Contact: Julie@medshadow.org / 347-239-0249